PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportsurologic neoplasms
MeSH D014571 - urologic neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D014565:Urogenital neoplasms
0 Companies
0 Drugs
Success rate
D014570:Urologic diseases
0 Companies
0 Drugs
Success rate
D014571: 
Urologic neoplasms
$
Success rate
D001749:Urinary bladder neoplasms
D007680:Kidney neoplasms
$
Success rate
D014516:Ureteral neoplasms
$
Success rate
D014523:Urethral neoplasms
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Astellas PharmaEnfortumab vedotin Padcev  2022-04-13   
Bristol Myers SquibbNivolumab Opdivo  2015-06-19 $9,212 M Q4/23-Q3/24 
Laboratoires Pierre FabreVinflunine Javlor  2009-09-21   
Merck & CoPembrolizumab Keytruda  2015-07-17 $28,253 M Q4/23-Q3/24 
RocheAtezolizumab Tecentriq  2017-09-20 $4,406.336 M Q4/22-Q3/23 
Clinical Trials
Historical Success Rate
Phase 1
66%
57/87
Phase 2
19%
20/103
Phase 3
36%
9/25
Approved: 6Overall Success rate: 5%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Astellas Pharma
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use